Table 5.

Comparison of coinfected patients with at least 2 Ishak fibrosis point progression and those that did not progress.

Characteristic	Non-Progressors (n=59)1	Progressors (n=7)	P	N
Age (years)1	44 (8)	43 (14)	0.88	59 & 7
Male (%)2	73 (60–84)	71 (29–96)	1	59 & 7
Caucasian (%)2	20 (11–33)	14 (0–58)	1	59 & 7
Weight (kg)1	78 (16)	67 (12)	0.061	58 & 7
Body mass index1	27 (5.2)	22 (2.6)	0.011	53 & 7
Alcohol abuse (%)2	22 (12–35)	14 (0–58)	1	59 & 7
HCV genotype 1 (%)2	94 (84–99)	86 (42–100)	0.41	52 & 7
HAART use (%)2	78 (65–88)	86 (42–100)	1	59 & 7
NRTI (%)2	78 (65–88)	86 (42–100)	1	59 & 7
NNRTI (%)2	29 (18–42)	43 (10–82)	0.43	59 & 7
PI (%)3	37 (25–51)	43 (10–82)	1	59 & 7
HIV < 400 (%)2	50 (35–65)	60 (15–95)	1	44 & 5
HIV titer longitudinal summary2
0–400	0–400: 51 (37–64)	0–400: 57 (18–90)
mixed4	mixed: 25 (15–38)	mixed: 43 (10–82)
400+	400+: 24 (14–37)	400+: 0	0.34	59 & 7
CD4 (cells/microliter)3	510 (290–700)	380 (320–470)	0.32	52 & 7
CD4 (cells/microliter)
AUC3	510 (350–740)	350 (300–570)	0.28	59 & 7
APRI3	0.66 (0.44–1.3)	0.84 (0.55–1.4)	0.59	56 & 7
APRI AUC3	0.65 (0.42–1.1)	0.76 (0.64–0.92)	0.39	59 & 7
Platelet (cells/microliter)1	220 (68)	190 (80)	1	56 & 7
Platelet (cells/microliter)
AUC1	210 (56)	180 (64)	0.3	59 & 7
ALT (U/L)3	82 (51–120)	64 (38–100)	0.27	56 & 7
ALT AUC3	70 (52–92)	56 (52–73)	0.29	59 & 7
AST (U/L)3	68 (48–110)	77 (66–85)	0.98	56 & 7
AST AUC3	66 (50–93)	62 (59–77)	0.81	59 & 7
ALP (U/L)3	110 (90–140)	130 (110–160)	0.27	56 & 7
ALP AUC3	100 (85–140)	140 (100–150)	0.26	59 & 7
FIB-43	1.8 (1.1–2.9)	1.8 (1.4–5)	0.62	56 & 7
FIB-4 AUC3	1.8 (1.3–2.4)	2.2 (1.5–3.3)	0.4	58 & 7
Total HAI inflammation1	6.5 (2.9)	4.4 (3.1)	0.09	59 & 7
Piecemeal necrosis1	2.1 (1.3)	1 (1.4)	0.059	59 & 7
Lobular inflammation1	2 (1.2)	1.6 (0.98)	0.33	59 & 7
Portal inflammation1	2.4 (1)	1.9 (1.1)	0.16	59 & 7
Ishak fibrosis stage (%)2
0	0: 14 (6–25)	0: 29 (4–71)	0.28	59 & 7
1	1: 36 (24–49)	1: 43 (10–82)
2	2: 27 (16–40)	2: 0
3	3: 14 (6–25)	3: 29 (4–71)
4	4: 10 (4–21)	4: 0
5	5: 0	5: 0
6	6: 0	6: 0
Steatosis > 5% (%)2	20 (11–33)	17 (0–64)	1	59 & 6
Interval between biopsies (years)1	4.6 (2.3)	5.1 (2.6)	0.78	59 & 7
Not treated for HCV (%)2	49 (36–63)	57 (18–90)	1	59 & 7
Sustained viral response (%)2	10 (4–21)	0 (0–41)	1	59 & 7

¹Mean (SD).

²Percent (95% confidence interval).

³Median (IQR).

⁴“Mixed” means that over the course of the study a patient was sometimes over 400 and sometimes under.